Home › Research › Treatments
Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial
Rockwood K, Fay S, Jarrett P, Asp E.. Neurology, 2007-04-01
Topic: Brain proteins, microglia and lab models
Objectives To understand how commonly diminution of verbal repetition was a goal of treatment in patients with Alzheimer disease (AD), how commonly that goal was achieved, whether goal attainment might be attributable to galantamine treatment, and whether change in verbal repetition is a marker of the overall treatment response. Methods This is a secondary analysis of the Video-Imaging Synthesis of Treating Alzheimer's Disease study, a 4-month, double-blind, randomized, placebo-controlled trial of galantamine in 130 community-dwelling patients with mild to moderate AD. The primary outcome was Goal Attainment Scaling, in which individualized problems identified by patients/caregivers and treating physicians were assessed bimonthly. Results Reduction of verbal repetition was set as a treatment goal in 44% (n = 57) of randomized patients. More patients/caregivers (32%) set repetition goals than did physicians (18%). After 4 months, more galantamine-treated patients showed diminution of verbal repetition (58%) than did placebo-treated patients (24%; p Conclusions Reduction of verbal repetition is a common goal of Alzheimer disease treatment. After 4 months, patients treated with galantamine were more likely to experience a reduction of verbal repetition than those treated with placebo. Diminution of verbal repetition was associated with other improvements, suggesting it might be a clinical marker of a positive treatment response.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rockwood, K., Fay, S., Jarrett, P., & Asp, E. (2007). Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology. https://doi.org/10.1212/01.wnl.0000258661.61577.b7
Vancouver
Rockwood K, Fay S, Jarrett P, Asp E. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology. 2007. doi:10.1212/01.wnl.0000258661.61577.b7. PMID: 17404193.
BibTeX
@article{rockwood2007-17404193,
author = {Rockwood, K. and Fay, S. and Jarrett, P. and Asp, E.},
title = {{Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial}},
journal = {Neurology},
year = {2007},
doi = {10.1212/01.wnl.0000258661.61577.b7},
pmid = {17404193},
url = {https://doi.org/10.1212/01.wnl.0000258661.61577.b7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Objectives To understand how commonly diminution of verbal repetition was a goal of treatment in patients with Alzheimer disease (AD), how commonly that goal was achieved, whether goal attainment might be attributable to galantamine treatment, and whether change in verbal repetition is a marker of the overall treatment response.
- Results Reduction of verbal repetition was set as a treatment goal in 44% (n = 57) of randomized patients.
- Diminution of verbal repetition was associated with other improvements, suggesting it might be a clinical marker of a positive treatment response.
Why it matters
In this secondary analysis of a 4-month trial, more galantamine-treated patients had a reduction in verbal repetition than placebo-treated patients. This concerns a specific symptom goal in mild to moderate Alzheimer's disease and does not show that galantamine cures or prevents it.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants57
- Evidence strengthHigh
How this study scored 61/100
Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2007 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 57 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 50 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.4 citations a year over 21 year(s) since 2007 |
| Impact for its field and year | 2 / 6 | Cited 2.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Elissa Asp: h-index 8 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Dalhousie University: institution h-index 778 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 17404193) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Treatments
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.